BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25678855)

  • 1. Clinical and laboratory features of seven patients with acute myeloid leukemia (AML)-M2/M3 and elevated myeloblasts and abnormal promyelocytes.
    He G; Wang C; Li Q; Tan H; Chen F; Huang Z; Yu B; Zheng L; Zheng R; Liu D
    Cancer Cell Int; 2014; 14(1):111. PubMed ID: 25678855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RARalpha rearrangement in newly diagnosed AML. The Medical Research Council (MRC) Adult Leukaemia Working Party.
    Allford S; Grimwade D; Langabeer S; Duprez E; Saurin A; Chatters S; Walker H; Roberts P; Rogers J; Bain B; Patterson K; McKernan A; Freemont P; Solomon E; Burnett A; Goldstone A; Linch D
    Br J Haematol; 1999 Apr; 105(1):198-207. PubMed ID: 10233384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AML1/ETO Fusion Gene in de novo Pediatric Acute Myeloid Leukemia: Clinical Significance and Prognostic Implications.
    Abdel Rahman H; Farrag SA; El-Attar IA
    J Egypt Natl Canc Inst; 2007 Mar; 19(1):39-47. PubMed ID: 18839034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Fluorescence in situ hybridization study of acute myeloid leukemia with cryptic chromosome rearrangements].
    Bai SX; Xue YQ; Chen SN; Pan JL; Wu YF; Shen J; Wang Y; Zhang J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Dec; 28(6):690-3. PubMed ID: 22161107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia.
    Cho EK; Bang SM; Ahn JY; Yoo SM; Park PW; Seo YH; Shin DB; Lee JH
    Korean J Intern Med; 2003 Mar; 18(1):13-20. PubMed ID: 12760263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute promyelocytic leukemia M3: cytomorphologic, immunophenotypic, cytogenetic, and molecular variants.
    Sucić M; Zadro R; Burazer B; Labar B; Nemet D; Mrsić M; Aurer I; Mrsić S; Hitrec V; Boban D; Marković-Glamocak M; Batinić D; Uzarević B; Stavljenić-Rukavina A
    J Hematother Stem Cell Res; 2002 Dec; 11(6):941-50. PubMed ID: 12590709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities.
    Khalidi HS; Medeiros LJ; Chang KL; Brynes RK; Slovak ML; Arber DA
    Am J Clin Pathol; 1998 Feb; 109(2):211-20. PubMed ID: 9583894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characteristics and Prognosis of 24 Cases of Primary Acute Myeloid Leukemia with Trisomy 8].
    Wang JH; Yao B; Guo M; Qiao JH; Sun QY; Hu KX; Li BX; Yu CL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):655-61. PubMed ID: 27342486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haematological & molecular profile of acute myelogenous leukaemia in India.
    Sazawal S; Kumar B; Hasan SK; Dutta P; Kumar R; Chaubey R; Mir R; Saxena R
    Indian J Med Res; 2009 Mar; 129(3):256-61. PubMed ID: 19491417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization.
    Klaus M; Haferlach T; Schnittger S; Kern W; Hiddemann W; Schoch C
    Cancer Genet Cytogenet; 2004 Nov; 155(1):47-56. PubMed ID: 15527902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of assessing cytogenetic and molecular risk factors in acute myeloid leukemia therapy.
    Coles EC; Colita A; Momanu R; Berbec N; Ivanescu AM; Oprea M; Jardan D; Jardan C; Arghir A; Coriu D; Lupu AR
    J Med Life; 2012; 5(Spec Issue):36-43. PubMed ID: 31803284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Correlation of immunophenotype to cytogenetics and clinical features of adult acute myeloid leukemia].
    Wang XB; Zheng JE; Gu JX; Yao JX; Yang J; Liu J; Li XQ; He YL; Yu JM; Wei J; Liu ZP; Huang SA
    Ai Zheng; 2005 Jun; 24(6):667-71. PubMed ID: 15946475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlations Between
    Wang XM; Ye YX; Yang L; Lu XJ; Ying BW
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 Nov; 47(6):931-935. PubMed ID: 28598127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All-trans retinoic acid as a single agent induces complete remission in a patient with acute leukemia of M2a subtype.
    Chen Z; Wang Y; Wang W; Gong J; Xue Y
    Chin Med J (Engl); 2002 Jan; 115(1):58-61. PubMed ID: 11930660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group.
    Haferlach T; Gassmann W; Löffler H; Jürgensen C; Noak J; Ludwig WD; Thiel E; Haase D; Fonatsch C; Becher R
    Ann Hematol; 1993 Apr; 66(4):165-70. PubMed ID: 8485203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High degree of myeloid differentiation and granulocytosis is associated with t(8;21) smoldering leukemia.
    Yamasaki H; Era T; Asou N; Sanada I; Matutes E; Yamaguchi K; Takatsuki K
    Leukemia; 1995 Jul; 9(7):1147-53. PubMed ID: 7630188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements.
    Orfao A; Chillón MC; Bortoluci AM; López-Berges MC; García-Sanz R; Gonzalez M; Tabernero MD; García-Marcos MA; Rasillo AI; Hernández-Rivas J; San Miguel JF
    Haematologica; 1999 May; 84(5):405-12. PubMed ID: 10329918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The use of quantitative assessment of Wilms tumour gene 1 for monitoring of residual disease in acute myeloid leukemia patients].
    Polák J; Marková J; Schwarz J; Maaloufová J; Volková Z; Cermák J; Haskovec C
    Cas Lek Cesk; 2006; 145(1):36-42. PubMed ID: 16468240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts.
    Testa U; Grignani F; Samoggia P; Zanetti C; Riccioni R; Lo Coco F; Diverio D; Felli N; Passerini CG; Grell M; Pelicci PG; Peschle C
    J Clin Invest; 1998 May; 101(10):2278-89. PubMed ID: 9593784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunophenotypes, cytogenetics and clinical features of 192 patients with acute myeloid leukemia].
    Tong HX; Wang HH; Zhang JH; Liu ZG; Zheng YC; Wang YX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1174-8. PubMed ID: 19840445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.